|
1
|
Shi K, Wang SL, Shen B, Yu FQ, Weng DF and
Lin JH: Clinicopathological and prognostic values of fibronectin
and integrin αvβ3 expression in primary osteosarcoma. World J Surg
Oncol. 17:232019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lokau J, Schoeder V and Garbers C: The
role of interleukin-11 in osteosarcoma. Pathologe. 41:163–167.
2020.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mason NJ: Comparative immunology and
immunotherapy of canine osteosarcoma. Adv Exp Med Biol.
1258:199–221. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin CH, Guo Y, Ghaffar S, McQueen P,
Pourmorady J, Christ A, Rooney K, Ji T, Eskander R, Zi X and Hoang
BH: Dkk-3, a secreted wnt antagonist, suppresses tumorigenic
potential and pulmonary metastasis in osteosarcoma. Sarcoma.
2013:1475412013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Czarnecka AM, Synoradzki K, Firlej W,
Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P:
Molecular biology of osteosarcoma. Cancers (Basel). 12:21302020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han G, Wang Y and Bi W: C-Myc
overexpression promotes osteosarcoma cell invasion via activation
of MEK-ERK pathway. Oncol Res. 20:149–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maire G, Martin JW, Yoshimoto M,
Chilton-MacNeill S, Zielenska M and Squire JA: Analysis of
miRNA-gene expression-genomic profiles reveals complex mechanisms
of microRNA deregulation in osteosarcoma. Cancer Genet.
204:138–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun ZY, Jian YK, Zhu HY and Li B:
lncRNAPVT1 targets miR-152 to enhance chemoresistance of
osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT
pathway. Pathol Res Pract. 215:555–563. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun Y, Jiang T, Jia Y, Zou J, Wang X and
Gu W: LncRNA MALAT1/miR-181a-5p affects the proliferation and
adhesion of myeloma cells via regulation of Hippo-YAP signaling
pathway. Cell Cycle. 18:2509–2523. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnson R and Halder G: The two faces of
Hippo: Targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chai J, Xu S and Guo F: TEAD1 mediates the
oncogenic activities of Hippo-YAP1 signaling in osteosarcoma.
Biochem Biophys Res Commun. 488:297–302. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan LH, Wang W, Yeung W, Deng Y, Yuan P
and Mak KK: Hedgehog signaling induces osteosarcoma development
through Yap1 and H19 overexpression. Oncogene. 33:4857–4866. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kyriazoglou A, Liontos M, Zakopoulou R,
Kaparelou M, Tsiara A, Papatheodoridi AM, Georgakopoulou R and
Zagouri F: The role of the hippo pathway in breast cancer
carcinogenesis, prognosis, and treatment: A systematic review.
Breast Care (Basel). 16:6–15. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zanconato F, Forcato M, Battilana G,
Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M
and Piccolo S: Genome-wide association between YAP/TAZ/TEAD and
AP-1 at enhancers drives oncogenic growth. Nat Cell Biol.
17:1218–1227. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Ramakrishnan SK, Triner D,
Centofanti B, Maitra D, Győrffy B, Sebolt-Leopold JS, Dame MK,
Varani J, Brenner DE, et al: Tumor-selective proteotoxicity of
verteporfin inhibits colon cancer progression independently of
YAP1. Sci Signal. 8:ra982015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen WS, Cao Z, Krishnan C and Panjwani N:
Verteporfin without light stimulation inhibits YAP activation in
trabecular meshwork cells: Implications for glaucoma treatment.
Biochem Biophys Res Commun. 466:221–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Andrade D, Mehta M, Griffith J,
Panneerselvam J, Srivastava A, Kim TD, Janknecht R, Herman T,
Ramesh R and Munshi A: YAP1 inhibition radiosensitizes triple
negative breast cancer cells by targeting the DNA damage response
and cell survival pathways. Oncotarget. 8:98495–98508. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan W, Wang Q, Zhang Y, Zhang N, Qin J, Li
W, Wang J, Wu F, Cao L and Xu G: Verteporfin can reverse the
paclitaxel resistance induced by YAP over-expression in HCT-8/T
cells without photoactivation through inhibiting YAP expression.
Cell Physiol Biochem. 39:481–490. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu Q, Lv G, Kim A, Ha JM and Kim S:
Expression and clinical significance of extracellular matrix
metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.
Oncol Lett. 5:201–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang DY, Wu YN, Huang JQ, Wang W, Xu M,
Jia JP, Han G, Mao BB and Bi WZ: Hippo/YAP signaling pathway is
involved in osteosarcoma chemoresistance. Chin J Cancer. 35:472016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun D, Wang Y, Wang H and Xin Y: The novel
long non-coding RNA LATS2-AS1-001 inhibits gastric cancer
progression by regulating the LATS2/YAP1 signaling pathway via
binding to EZH2. Cancer Cell Int. 20:2042020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu YP, Pan LL and Kong CC: Stathmin 1
promotes the progression of liver cancer through interacting with
YAP1. Eur Rev Med Pharmacol Sci. 24:7335–7344. 2020.PubMed/NCBI
|
|
26
|
Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang
Y, Pizzi MP, Scott A, Harada K, Ma L, et al: YAP1 mediates gastric
adenocarcinoma peritoneal metastases that are attenuated by YAP1
inhibition. Gut. 70:55–66. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Y, Huang T, Cheng AS, Yu J, Kang W
and To KF: The TEAD family and its oncogenic role in promoting
tumorigenesis. Int J Mol Sci. 17:1382016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou Y, Huang T, Zhang J, Wong CC, Zhang
B, Dong Y, Wu F, Tong JHM, Wu WKK, Cheng ASL, et al: TEAD1/4 exerts
oncogenic role and is negatively regulated by miR-4269 in gastric
tumorigenesis. Oncogene. 36:6518–6530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng Y and Pan D: The hippo signaling
pathway in development and disease. Dev Cell. 50:264–282. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Xu X, Maglic D, Dill MT, Mojumdar
K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, et al:
Comprehensive molecular characterization of the hippo signaling
pathway in cancer. Cell Rep. 25:1304–1317.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yimlamai D, Fowl BH and Camargo FD:
Emerging evidence on the role of the Hippo/YAP pathway in liver
physiology and cancer. J Hepatol. 63:1491–1501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Plouffe SW, Hong AW and Guan KL: Disease
implications of the Hippo/YAP pathway. Trends Mol Med. 21:212–222.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hong L, Cai Y, Jiang M, Zhou D and Chen L:
The Hippo signaling pathway in liver regeneration and
tumorigenesis. Acta Biochim Biophys Sin (Shanghai). 47:46–52. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu K, Du S, Gao P and Zheng J:
Verteporfin suppresses the proliferation, epithelial-mesenchymal
transition and stemness of head and neck squamous carcinoma cells
via inhibiting YAP1. J Cancer. 10:4196–4207. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park MH, Kim AK, Manandhar S, Oh SY, Jang
GH, Kang L, Lee DW, Hyeon DY, Lee SH, Lee HE, et al: CCN1
interlinks integrin and hippo pathway to autoregulate tip cell
activity. Elife. 8:e460122019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou X, Rao Y, Sun Q, Liu Y, Chen J and Bu
W: Long noncoding RNA CPS1-IT1 suppresses melanoma cell metastasis
through inhibiting Cyr61 via competitively binding to BRG1. J Cell
Physiol. 234:22017–22027. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie L, Song X, Lin H, Chen Z, Li Q, Guo T,
Xu T, Su T, Xu M, Chang X, et al: Aberrant activation of CYR61
enhancers in colorectal cancer development. J Exp Clin Cancer Res.
38:2132019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fromigue O, Hamidouche Z, Vaudin P,
Lecanda F, Patino A, Barbry P, Mari B and Marie PJ: CYR61
downregulation reduces osteosarcoma cell invasion, migration, and
metastasis. J Bone Miner Res. 26:1533–1542. 2011. View Article : Google Scholar : PubMed/NCBI
|
